BioAlliance Pharma announced the signature of an exclusive pharma licensing agreement for Sitavig (Acyclovir Lauriad) with Abic Marketing Limited, a group subsidiary of Teva Pharmaceutical Industries for commercialization rights in Israel.
BioAlliance Pharma has conceived and developed Sitavig for the treatment of recurrent labial herpes in immunocompetent patients presenting more than 4 episodes a year.
Financial terms of this pharma licensing agreement are not publicly disclosed.
This pharma licensing agreement includes upfront and milestone payments as well as royalties on sales in Israel, to be paid to BioAlliance Pharma by Teva.
For further deal information visit Current Agreements (subscription required)
Read: more on partnering deals in pharma, biotech, life science partnering deal news, insights and glossary
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity